A citation-based method for searching scientific literature

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 104



Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó, Thomas Danne, Darren K McGuire, Jake A Kushner, Anne Peters, Paul Strumph. N Engl J Med 2017
Times Cited: 211




List of shared articles



Times cited

Double Diabetes: A Growing Problem Requiring Solutions.
Djordje S Popovic, Nikolaos Papanas. Exp Clin Endocrinol Diabetes 2022
0

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience.
Ana Palanca, Falco van Nes, Felipe Pardo, F Javier Ampudia Blasco, Chantal Mathieu. Diabetes Care 2022
4

The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Saniya Tandon, Salma Ayis, David Hopkins, Seeromanie Harding, Marietta Stadler. Diabetes Obes Metab 2021
4

Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao, Zhiguang Zhou. J Diabetes Investig 2021
2


The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
Józef Drzewoski, Markolf Hanefeld. Pharmaceuticals (Basel) 2021
15

Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.
Biff F Palmer, Deborah J Clegg. Clin J Am Soc Nephrol 2021
6

Current and future therapies for type 1 diabetes.
Bernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, Matthias von Herrath. Diabetologia 2021
14


Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.
Ghasem Yadegarfar, Mark Livingston, Gabriela Cortes, Ramadan Alshames, Kate Leivesley, Ann Metters, Linda Horne, Tom Steele, Adrian H Heald. Cardiovasc Endocrinol Metab 2021
1

Using adjuvant pharmacotherapy in the treatment of type 1 diabetes.
Åke Sjöholm. Expert Opin Pharmacother 2021
0

Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges.
Nuria Vilarrasa, Patricia San Jose, Miguel Ángel Rubio, Albert Lecube. Diabetes Metab Syndr Obes 2021
3

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
David Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal. Diabetes Obes Metab 2021
2


Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Thomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, Frederik F Kreiner, Lars Bardtrum, Matthias von Herrath, Chantal Mathieu, Sten Madsbad. Diabetes Obes Metab 2021
0

Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
2


Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
Johan H Jendle, Francisco J Ampudia-Blasco, Martin Füchtenbusch, Paolo Pozzilli. touchREV Endocrinol 2021
0

Past, present and future of latent autoimmune diabetes in adults.
Bingwen Liu, Yufei Xiang, Zhenqi Liu, Zhiguang Zhou. Diabetes Metab Res Rev 2020
17

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Christian Hampp, Richard S Swain, Casie Horgan, Elizabeth Dee, Yandong Qiang, Sarah K Dutcher, Andrew Petrone, Rong Chen Tilney, Judith C Maro, Catherine A Panozzo. Diabetes Care 2020
20

12th Roche Diabetes Care Network Meeting: April 11-13, 2019, Copenhagen, Denmark.
Christopher G Parkin, Christine Zepezauer, Rolf Hinzmann. Diabetes Technol Ther 2020
0

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
16

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer R Snaith, Deborah J Holmes-Walker, Jerry R Greenfield. Trends Endocrinol Metab 2020
11

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
19


Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
Kana N Miyata, Shuiling Zhao, Chin-Han Wu, Chao-Sheng Lo, Anindya Ghosh, Isabelle Chenier, Janos G Filep, Julie R Ingelfinger, Shao-Ling Zhang, John S D Chan. Diabetes Res Clin Pract 2020
4

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
3

Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
7

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
4

Pharmacological therapies to address obesity in type 1 diabetes.
Anna Casu, Anika Bilal, Richard E Pratley. Curr Opin Endocrinol Diabetes Obes 2020
2



SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
8

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.
Raffaella Buzzetti, Tiinamaija Tuomi, Didac Mauricio, Massimo Pietropaolo, Zhiguang Zhou, Paolo Pozzilli, Richard David Leslie. Diabetes 2020
38

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes.
Pieter Gillard, Oliver Schnell, Per-Henrik Groop. Diabetes Res Clin Pract 2020
5


An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
1


Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.
Stephan Siebel, Alfonso Galderisi, Neha S Patel, Lori R Carria, William V Tamborlane, Jennifer L Sherr. Diabetes Technol Ther 2019
1

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
135

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa Lalic, Dario Rahelic, Jan Skrha, Paul Valensi, Antonio Ceriello. Cardiovasc Diabetol 2019
21



Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
6


SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.
Joseph I Wolfsdorf, Robert E Ratner. Diabetes Care 2019
16

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
7



Defining and characterising diabetic ketoacidosis in adults.
Ketan K Dhatariya. Diabetes Res Clin Pract 2019
19